ArticleNPJ vaccines2024
Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines.
Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Seasonal influenza mRNA vaccine induces stronger innate and comparable or better adaptive responses than licensed inactivated vaccines.NPJ vaccines · 2026Article
- Influenza mRNA vaccine with engineered panhandle-forming UTRs provides potent, dose-sparing protection against seasonal influenza viruses.NPJ vaccines · 2026Article
- Preclinical evaluation of an mRNA vaccine developed from the first human isolate of bovine H5N1.Cell reports. Medicine · 2026Article
- Next-generation mucosal vaccines for respiratory viruses: Immunological correlates, platform design and clinical translation.World journal of virology · 2026Review
- Evaluating southern pigtail macaques as an immunological model for human antibody responses.Scientific reports · 2026Article
- A VLP-based mRNA vaccine elicits potent humoral and cellular immunity against Oropouche virus.mBio · 2026Article
- Intranasal replicon vaccine establishes mucosal immunity and protects against H5N1 and H7N9 influenza.Nature communications · 2026Article
- mRNA-based seasonal influenza vaccines: an overview of immunogenicity, efficacy, and safety.Frontiers in immunology · 2026Review
- Preclinical immunogenicity and safety evaluation of MDCK cell-derived quadrivalent influenza virus subunit vaccine.Frontiers in immunology · 2026Article
- Current status of H5N1 influenza vaccines against clade 2.3.4.4b of H5N1.New microbes and new infections · 2025Article
- Influenza mRNA vaccine reduces pathogenicity and transmission of A(H5N1) virus in a ferret model.NPJ vaccines · 2025Article
- Article
- A novel in-vitro expression assay by LC/MS/MS enables multi-antigen mRNA vaccine characterization.Scientific reports · 2025Article
- A highly stable lyophilized mRNA vaccine for Herpes Zoster provides potent cellular and humoral responses.NPJ vaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seasonal epidemics of influenza viruses are responsible for a significant global public health burden. Vaccination remains the most effective way to prevent infection; however, due to the persistence of antigenic drift, vaccines must be updated annually. The selection of vaccine strains occurs months in advance of the influenza season to allow adequate time for production in eggs. RNA vaccines offer the potential to accelerate production and improve efficacy of influenza vaccines. We leveraged the nucleoside-modified RNA (modRNA) platform technology and lipid nanoparticle formulation process of the COVID-19 mRNA vaccine (BNT162b2; Comirnaty®) to create modRNA vaccines encoding hemagglutinin (HA) (modRNA-HA) for seasonal human influenza strains and evaluated their preclinical immunogenicity and toxicity. In mice, a monovalent modRNA vaccine encoding an H1 HA demonstrated robust antibody responses, HA-specific Th1-type CD4
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.